Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · IEX Real-Time Price · USD
62.93
+4.40 (7.52%)
At close: Apr 26, 2024, 4:00 PM
62.86
-0.07 (-0.11%)
After-hours: Apr 26, 2024, 6:06 PM EDT
Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.
Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Korro Bio, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Ram Aiyar MBA, Ph.D. |
Contact Details
Address: One Kendall Square. Building 600-700, Suite 6-401 Cambridge, Massachusetts 02139 United States | |
| Phone | 617-468-1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001703647 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nessan Bermingham Ph.D. | Co-Founder and Executive Chairman |
| Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President and Director |
| Dr. Jean-Francois Formela M.D., MBA | Co-Founder and Director |
| Vineet Agarwal M.B.A. | Chief Financial Officer |
| Dr. Steven L. Colletti Ph.D. | Chief Scientific Officer |
| Andrew Fraley Ph.D. | Co-Founder and Chief Technology Officer |
| Josh Rosenthal Ph.D. | Co-Founder and Advisor |
| Todd Chappell | Chief Operating Officer |
| Shelby Walker J.D. | Senior Vice President and General Counsel |
| Ravi Ramadas Ph.D. | Vice President of Business and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 24, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 22, 2024 | 424B3 | Prospectus |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 18, 2024 | 424B3 | Prospectus |
| Apr 18, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 27, 2024 | EFFECT | Notice of Effectiveness |
| Mar 26, 2024 | POS AM | Post-Effective amendments for registration statement |